Despite an increase in the incidence of advanced and metastatic rectal cancer, overall survival has improved, probably because of improvements in treatment, a new analysis concludes.
Half of patients with unresectable, locally recurrent CRC were alive at 5 years, a notable improvement over standard treatment. The study was published as a preprint and has not been peer reviewed.
Patients with stage IIA and IIB esophageal squamous cell carcinoma with lymphovascular invasion but negative lymph nodes do not benefit. The study was published as a preprint and has not yet been peer reviewed.